Pharmafile Logo
Pharmafocus logo
Advanced Search

Novimmune

Showing 1 posts of 1 posts found.

FDA approves first ever therapy for ultra rare primary haemophagocytic lymphohistiocytosis

November 21, 2018
Research and Development, Sales and Marketing FDA, Novimmune, pharma, sobi

The partnership of Sobi and Novimmune has revealed that their interferon gamma (IFNγ) blocking antibody Gamifant (emapalumab-lzsg) has received approval …

News
The Gateway to Local Adoption Series

Latest content

MRM Health’s ulcerative colitis treatment receives FDA Investigational New Drug clearance

January 27, 2026

Crystalys Therapeutics appoints Justin Thacker as Chief Financial Officer

January 27, 2026

Rentschler Biopharma appoints Uwe Buecheler as interim CEO

January 26, 2026

Sandoz’ Ondibta receives European Commission approval for diabetes

January 26, 2026

Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation

January 22, 2026